Structure-guided residence time optimization of a dabigatran reversal agent
Felix Schiele(Boehringer Ingelheim (Germany)), Herbert Nar(Boehringer Ingelheim (Germany)), Daniel Seeliger(Boehringer Ingelheim (Germany)), Tobias Litzenburger(Boehringer Ingelheim (Germany)), Michael Ritter(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joanne van Ryn(Boehringer Ingelheim (Brazil))
Cited by 14
Related Papers
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
|New England Journal of Medicine|2017|1.1k
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383